Male patients aged ≥60 years.

ECOG performance status score of 0 ~1.

Expected survival time of more than 3 months.

Histologically or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.

Patients who have not previously received any anti-PD-1 treatment.

Patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria.

At least one tumor lesion meeting the following criteria:

• No prior local treatments such as radiotherapy
• Not biopsied during the screening period (if biopsy needed, baseline tumor assessment at least 14 days after the screening biopsy).
• Measurable at baseline (longest diameter of the lesion ≥10 mm; For a lymph node, short diameter ≥15 mm).
• If only one measurable lesion, no prior local treatments such as radiotherapy.

Ability to understand and voluntarily sign a written informed consent form.

Willingness to follow the study protocol and follow-up examinations.